Welcome to our dedicated page for ONWARD Medical NV news (Ticker: ONWRY), a resource for investors and traders seeking the latest updates and insights on ONWARD Medical NV stock.
ONWARD Medical N.V. (US ADR: ONWRY, Euronext: ONWD) regularly publishes news about its neurotechnology therapies for people with spinal cord injuries (SCI) and other movement disabilities. Company updates highlight progress with ARC Therapy, including the non-invasive ARC-EX® System and the investigational implantable ARC-IM® and ARC-BCI® platforms.
News items often cover commercial traction for the ARC-EX System, such as the number of systems sold to US clinics and the expansion of access across dozens of rehabilitation centers. Releases also describe regulatory developments, including FDA 510(k) clearance for ARC-EX, CE Mark certification in the European Union, and an Investigational Device Exemption (IDE) for ARC-IM that enables the Empower BP global pivotal study for blood pressure instability after SCI.
Another recurring theme in ONWARD Medical’s news flow is science and technology leadership. The company reports results from pivotal and feasibility studies like Up-LIFT and Pathfinder2, as well as landmark publications in journals such as Nature, Nature Medicine, and Neurology: Clinical Practice. These articles, as summarized in press releases, describe outcomes related to hand strength and sensation, quality of life, upper body function, and blood pressure regulation.
Investors following ONWRY news will also find announcements about capital raises, private placements on Euronext markets, and the use of proceeds to fund product development, clinical trials, regulatory activities, and commercialization of ARC-EX in the US, Europe, and selected other geographies. Coverage notes the participation of institutional and sector-focused investors and mentions equity research initiation by banks.
This news page aggregates these company communications so readers can review updates on clinical milestones, regulatory decisions, commercialization progress, and financing activities related to ONWARD Medical and its ARC Therapy platform.
ONWARD Medical, a medical technology company specializing in spinal cord stimulation therapies, has announced its 2025 Annual General Meeting (AGM) scheduled for June 11, 2025, in Amsterdam. The company, trading as ONWD on Euronext and ONWRY on US OTCQX, will present twelve key voting items.
The agenda includes crucial resolutions such as:
- Adoption of 2024 financial accounts
- Compensation policy approval
- Re-appointment of key directors including David Marver and Ian Curtis
- New appointments of Rahma Samow and Robert ten Hoedt
- Authorization for share issuance up to 10% and 50% of capital
The record date is set for May 14, 2025. All AGM materials are available on the company's investor relations website, with US ADR holders receiving notice through Bank of New York Mellon.
ONWARD Medical N.V. (Euronext: ONWD), a medical technology company specializing in spinal cord stimulation therapies, has filed its 2024 Annual Report with the Dutch Authority for the Financial Markets (AFM). The company, which focuses on restoring movement and independence for people with spinal cord injury (SCI), has also published its 2024 Sustainability Report.
The company received recognition for its sustainability efforts in 2024, earning a silver medal from EcoVadis, the world's largest business sustainability ratings provider. CEO Dave Marver described 2024 as a transformative year for ONWARD in advancing their mission.
Stakeholders can access the 2024 Annual Report, Sustainability Summary, and a recording of the 2024 Full Year Results Webinar from April 1, 2025, on the company's Investor Relations webpage.
ONWARD Medical (Euronext: ONWD, OTCQX: ONWRY) has established a sponsored Level 1 American Depositary Receipt (ADR) program in the United States through the Bank of New York Mellon (BNY), with ADRs now trading on the OTCQX® Best Market under symbol ONWRY.
The medical technology company, which develops spinal cord stimulation therapies for movement restoration, aims to enhance US investor access through this program. One ONWARD ADR represents one ordinary share and is denominated in US dollars, making it easier for American investors to trade.
The ADR program and OTCQX upgrade are designed to broaden ONWARD's shareholder base and increase stock liquidity. BNY will serve as the depositary bank and transfer agent for the ADR program, with US investors able to access financial disclosure and Real-Time Level 2 quotes on otcmarkets.com.